Novartis Institutes for BioMedical Research Basel, Neuroscience Research, WSJ-386.743, Postfach, CH-4002 Basel, Switzerland.
Curr Neuropharmacol. 2007 Sep;5(3):187-94. doi: 10.2174/157015907781695900.
The metabotropic glutamate receptor family comprises eight subtypes (mGlu1-8) of G-protein coupled receptors. mGlu receptors have a large extracellular domain which acts as recognition domain for the natural agonist glutamate. In contrast to the ionotropic glutamate receptors which mediate the fast excitatory neurotransmission, mGlu receptors have been shown to play a more modulatory role and have been proposed as alternative targets for pharmacological interventions. The potential use of mGluRs as drug targets for various nervous system pathologies such as anxiety, depression, schizophrenia, pain or Parkinson's disease has triggered an intense search for subtype selective modulators and resulted in the identification of numerous novel pharmacological agents capable to modulate the receptor activity through an interaction at an allosteric site located in the transmembrane domain. The present review presents the most recent developments in the identification and the characterization of allosteric modulators for the mGlu receptors.
代谢型谷氨酸受体家族包括 8 种 G 蛋白偶联受体亚型(mGlu1-8)。mGlu 受体具有一个大的细胞外结构域,作为天然激动剂谷氨酸的识别结构域。与介导快速兴奋性神经传递的离子型谷氨酸受体不同,mGlu 受体被证明具有更调节性的作用,并被提议作为药理学干预的替代靶点。mGluRs 作为各种神经系统疾病(如焦虑、抑郁、精神分裂症、疼痛或帕金森病)的药物靶点的潜在用途,引发了对亚型选择性调节剂的强烈研究,并导致了许多能够通过位于跨膜域中的变构位点与受体相互作用来调节受体活性的新型药理学药物的鉴定。本综述介绍了代谢型谷氨酸受体变构调节剂的鉴定和表征的最新进展。